Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment Of Safety, Efficacy, PK&PD Of BG9924 in RA Patients Who Have Had An Inadequate Response To Conventional DMARD Therapy.

NCT00664716 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT00664716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00664716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment Of Safety, Efficacy, PK&PD Of BG9924 in RA Patients Who Have Had An Inadequate Response To Conventional DMARD Therapy.
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2007
Completion date
October 31, 2008
Enrollment
391 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis